Aaron Simoni

Aaron Simoni

Auto-generated profile, based on publicly available information

Aaron Simoni

Kidney and Urinary Tract Center, The Abigail Wexner Research Institute at Nationwide Children’s, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
ASAaron Simoni
Aaron Simoni
LSLaura Schwartz
Laura Schwartz
GJGuillermo Yepes Junquera
Guillermo Yepes Junquera
CCChristina B Ching
Christina B Ching
JSJohn Spencer
John Spencer

18 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LSLaura Schwartz
Laura Schwartz
MBM. Skye Bochter
M. Skye Bochter
ASAaron Simoni
Aaron Simoni
KBKristin Bender
Kristin Bender
JRJuan de Dios Ruiz Rosado
Juan de Dios Ruiz Rosado
JSJohn Spencer
John Spencer
With the emergence of antibiotic-resistant bacteria, innovative approaches are needed for the treatment of urinary tract infections. Boosting antimicrobial peptide expression may provide an alternative to antibiotics. Here, we developed reporter cell lines and performed a high-throughput screen of clinically used drugs to identify compounds that boost ribonuclease 4 and 7 expression (RNase 4 and 7), peptides that have antimicrobial activity against antibiotic-resistant uropathogens. This screen identified histone deacetylase (HDAC) inhibitors as effective RNase 4 and RNase 7 inducers. Validation studies in primary human kidney and bladder cells confirmed pan-HDAC inhibitors as well as the HDAC class I inhibitor, MS-275, induce RNase 4 and RNase 7 to protect human kidney and bladder cells from uropathogenic Escherichia coli . When we administered MS-275 to mice, RNase 4 and 7 expression increased and mice were protected from acute transurethral E. coli challenge. In support of this mechanism, MS-275 treatment increased acetylated histone H3 binding to the RNASE4 and RNASE7 promoters. Overexpression and knockdown of HDAC class I proteins identified HDAC3 as a primary regulator of RNase 4 and 7. These results demonstrate the protective effects of enhancing RNase 4 and RNase 7, opening the door to repurposing medications as antibiotic conserving therapeutics for urinary tract infection.

21 March 2024 in Cell Reports
Verified
Journal Article
Open access
LSLaura Schwartz
Laura Schwartz
KSKristin Salamon
Kristin Salamon
ASAaron Simoni
Aaron Simoni
TETad Eichler
Tad Eichler
AJAshley R. Jackson
Ashley R. Jackson
JSJohn Spencer
John Spencer
Urinary tract infections (UTIs) commonly afflict people with diabetes. To better understand the mechanisms that predispose diabetics to UTIs, we employ diabetic mouse models and altered insulin signaling to show that insulin receptor (IR) shapes UTI defenses. Our findings are validated in human biosamples. We report that diabetic mice have suppressed IR expression and are more susceptible to UTIs caused by uropathogenic Escherichia coli (UPEC). Systemic IR inhibition increases UPEC susceptibility, while IR activation reduces UTIs. Localized IR deletion in bladder urothelium promotes UTI by increasing barrier permeability and suppressing antimicrobial peptides. Mechanistically, IR deletion reduces nuclear factor κB (NF-κB)-dependent programming that co-regulates urothelial tight junction integrity and antimicrobial peptides. Exfoliated urothelial cells or urine samples from diabetic youths show suppressed expression of IR, barrier genes, and antimicrobial peptides. These observations demonstrate that urothelial insulin signaling has a role in UTI prevention and link IR to urothelial barrier maintenance and antimicrobial peptide expression.

8 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LSLaura Schwartz
Laura Schwartz
ASAaron Simoni
Aaron Simoni
PYpearlly yan
pearlly yan
KSKristin Salamon
Kristin Salamon
ATAltan Turkoglu
Altan Turkoglu
JSJohn Spencer
John Spencer
Urinary tract infection (UTI) commonly afflicts people with diabetes. This augmented infection risk is partly due to deregulated insulin receptor (IR) signaling in the kidney collecting duct. The collecting duct is composed of intercalated cells (ICs) and principal cells (PCs). Evidence suggests that ICs contribute to UTI defenses. Here, we interrogate how IR deletion in ICs impacts antibacterial defenses against uropathogenic Escherichia coli. We also explore how IR deletion affects immune responses in neighboring PCs with intact IR expression. To accomplish this objective, we profile the transcriptomes of IC and PC populations enriched from kidneys of wild-type and IC-specific IR knock-out mice that have increased UTI susceptibility. Transcriptomic analysis demonstrates that IR deletion suppresses IC-integrated stress responses and innate immune defenses. To define how IR shapes these immune defenses, we employ murine and human kidney cultures. When challenged with bacteria, murine ICs and human kidney cells with deregulated IR signaling cannot engage central components of the integrated stress response—including activating transcriptional factor 4 (ATF4). Silencing ATF4 impairs NFkB activation and promotes infection. In turn, NFkB silencing augments infection and suppresses antimicrobial peptide expression. In diabetic mice and people with diabetes, collecting duct cells show reduced IR expression, impaired integrated stress response engagement, and compromised immunity. Collectively, these translational data illustrate how IR orchestrates collecting duct antibacterial responses and the communication between ICs and PCs.

30 September 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
KSKristin Salamon
Kristin Salamon
SLSarah Linn‐Peirano
Sarah Linn‐Peirano
ASAaron Simoni
Aaron Simoni
JRJuan de Dios Ruiz‐Rosado
Juan de Dios Ruiz‐Rosado
BBBrian Becknell
Brian Becknell
JSJohn Spencer
John Spencer

23 July 2025 in Life Science Alliance
Verified
Journal Article
Open access
ASAaron Simoni
Aaron Simoni
MBM Skye Bochter
M Skye Bochter
SLSarah Linn-Peirano
Sarah Linn-Peirano
KSKristin Salamon
Kristin Salamon
BBBrian Becknell
Brian Becknell
JSJohn Spencer
John Spencer
Despite advancements in our understanding of urinary tract infection (UTI) pathogenesis, UTIs remain a leading cause of morbidity, partly because of an incomplete understanding of the molecular pathways governing bladder antibacterial defenses. Here, we demonstrate that phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/Akt signaling, is a critical modulator of bladder urothelial immune defenses and vulnerability to UTIs caused by uropathogenic Escherichia coli (UPEC). PTEN silencing in human bladder urothelial cells increases susceptibility to UPEC in vitro, and urothelial-specific PTEN knockout mice exhibit increased bacterial titers in the urine, bladder, and kidneys after in vivo transurethral UPEC infection. Mechanistically, PTEN deficiency enhances Akt phosphorylation, amplifying NFκB and FAK activity. Silencing NFκB or FAK in PTEN-deficient cells restores resistance to UPEC. These findings establish PTEN as an important regulator of bladder urothelial defenses, balancing immune activation and urothelial structural integrity to protect against UTI.